// App-Quantinova.ai

TPS373 : A phase 3 randomized, double-blind, placebo-controlled, multicenter, global study of durvalumab with and after chemoradiotherapy in patients with locally advanced, unresectable esophageal squamous cell carcinoma: KUNLUN.

Researchers

Presenter

  • Luhua Wang

Principal Investigators

  • Ming Chen

  • Ken Kato

  • Lucjan Wyrwicz

  • Elizabeth Catherine Smyth

  • Anastasia Jiang

  • Di Zhang

  • Scott H. Robbins

  • Philip He

  • Alejandra Negro

  • Nabil F. Saba

Medical Centers

  • Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

  • Cancer Hospital of Chinese Academy of Medical Sciences, Zhejiang Cancer Hospital, Hangzhou, China

  • Narodowy Instytut Onkologii im. Marii SkÅ‚odowskiej-Curie, Warsaw, Poland

  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

  • AstraZeneca, Shanghai, China

  • AstraZeneca, Gaithersburg, MD

  • Winship Cancer Institute of Emory University School of Medicine, Atlanta, GA

Locations

  • China

  • Japan

  • Poland

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Esophageal squamous carcinoma cell

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Fluorouracil

  • Adrucil injection

  • Capecitabine

  • Durvalumab

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT04550260

Sponsors

  • AstraZeneca.

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved